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Abstract
Backround:  A retrospective (case-controlled) study was conducted with the aim of  identifying the effect of  the use of  miso-
prostol on termination time in patients who did and did not undergo feticide procedures in second trimester pregnancy termi-
nations.  
Methods: The sampling of  the study consisted of  144 pregnant women who were diagnosed as having major fetal anomalies 
incompatible with life, and were recommended for termination of  pregnancy. The investigation showed that feticide procedures 
were performed for 99 women, and feticide procedures were not performed for 45 women. Misoprostol protocol was adminis-
tered for 48 hours in the termination period; whether the feticide procedure directly affected the termination duration in patients 
who did and did not undergo feticide was evaluated. 
Results: Abortion/birth was achieved in 103 (71.5%) women during the first 48 hours. There was no significant difference be-
tween the termination duration of  the misoprostol protocol among the women who did and did not undergo feticide. There was 
no significant difference between the termination durations and fetal biometric measurements (BPD, HC) except head diameters 
(p=0.020 and p=0.015). 
Conclusions: The misoprostol protocol is shown to be effective and safe for the termination of  pregnancies during the second 
trimester. Feticide has no affect on the duration of  termination. 
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Fetal abnormality is known to be a major cause of  peri-
natal mortality. Termination of  pregnancy for fetal ab-
normalities significantly decreases perinatal mortality 
resulting from birth defects1,2. Fetal morphologic anoma-
lies (without chromosomal anomalies) and chromosomal 
anomalies formed the main grounds for termination of  
pregnancy in 39% and 35% of  cases, respectively, in a 
study by Guillem et al.3 and 47% and 33%, respective-
ly, in another study by Ramalho et al.4. Pregnancies may 
need to be terminated during the second trimester due 
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to fetal or maternal reasons. Dilation and curettage is 
the most preferred method for the termination of  preg-
nancies during the first trimester, but termination with 
this method during the second trimester is likely to cause 
problems. The width of  fetal-placental units, increased 
uterine blood flow, and the unripe cervix complicate the 
procedure during the second trimester5. Termination 
during the second trimester is achieved with prostaglan-
dins in today’s world. Misoprostol (15-deoxy-16-hydroxy-
16-methyl prostaglandin E1) is a synthetic Prostaglandin 
E1 (PGE1) analogue. PGE1 is used in the induction of  
labor because of  its uterotonic effects and it provides cer-
vical ripening6. 
Due to easy storage at room temperature, cost-effective-
ness and availability, misoprostol is the drug of  choice. 
Misoprostol is successfully used in oral, sublingual, intra-
vaginal, intracervical, and rectal forms in the termination 
of  pregnancies7,8. However, there is no consensus about 
which route is the most effective and least likely to cause 
adverse effects in the termination of  second trimester 
pregnancies. The half  life of  oral misoprostol is 20-40 
minutes, the dose is between 200-800 μg, and application 
frequency is between 3-12 hours. Its adverse effects on 
the gastrointestinal system including nausea, vomiting, 
fatigue, trembling, and fever are limited6-8. If  the applica-
tion route is disregarded, the adverse effects are depen-
dent on the dose. 
We aimed to investigate the effect of  the use of  oral miso-
prostol after 200 mcg vaginal misoprostol (PGE1-Cyto-
tec) administration on the termination duration in pa-
tients who did and did not undergo feticide in second 
trimester pregnancy terminations.  
Materials and methods
The files of  905 pregnant women who presented to the 
pre-natal diagnosis unit in Süleymaniye Gynecology and 
Obstetrics Education and Training Hospital, and were 
diagnosed as having fetal anomalies in second trimester 
colour Doppler ultrasonography screening between 2009 
and 2014 were retrospectively investigated. 455 out of  
905 pregnant women were diagnosed as having major 
fetal anomalies incompatible with life, and were recom-
mended termination of  pregnancy. The ultrasonographic 
screening of  450 pregnant women revealed minor fetal 
anomalies compatible with life, and termination was not 
recommended. The detected major and minor anomalies 
were central nervous system anomalies, cardiovascular 
system anomalies, chromosomal anomalies detected in 
amniocentesis, skeletal system anomalies, and urinary sys-
tem anomalies. 
Two hundred fourteen out 455 pregnant women who 
were recommended termination accepted to terminate 
the pregnancy, and 241 pregnant women refused to ter-
minate pregnancy. One hundred forty-four pregnant 
women out of  214 who accepted termination were in-
cluded in the study in accordance with the sample inclu-
sion criteria. The inclusion criteria were pregnancies with 
fetal anomalies that were incompatible with life in the 
second trimester; being aged over 15 years; Bishop score 
of  3 or below in bimanual examination; and pregnancies 
with no placental location anomalies. The exclusion crite-
ria were the pregnancies with major fetal anomalies that 
were incompatible with life in the first and third trimester; 
being aged younger than 15 years; having been diagnosed 
with systemic and chronic diseases such as heart disease, 
diabetes mellitus, eclampsia-preeclampsia, and asthma; 
initiated active labor action; Bishop scoring over 3; preg-
nancies with minor or major fetal anomalies that were 
compatible with life.
The study was conducted in the perinatology and deliv-
ery room unit in Süleymaniye Gynecology and Obstet-
rics Education and Training Hospital after the approval 
of  the hospital education and planning board and ethics 
board were granted. 
Feticide procedures were performed (case group) for 
99 pregnant women out of  144 who were recommend-
ed termination. Feticide procedures were not performed 
(control group) for 45 pregnant women. The feticide 
procedures were performed by the same physician under 
transabdominal ultrasonography guidance with a percu-
taneous injection of  potassium chloride (KCL) solution 
(1.5 g KCL in 10 mL) to the fetal heart or umbilical cord 
using a 20-gauge spinal needle.
Bimanual examinations of  the pregnant women were 
performed in the delivery room unit. Two hundred mi-
crograms of  dry misoprostol (Cytotec ® 200 mcg tablet 
x 1, Ali Raif  Drug Industry Inc., Istanbul, Turkey) was 
placed into the vaginal posterior fornix. A maximum of  
4 doses of  oral 400 mcg misoprostol (Cytotec® 200 mcg 
tablet x, 1 Ali Raif  Drug Industry Inc., Istanbul, Turkey) 
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was administered every 4 hours to women who had no 
history of  previous cesarean section, and a maximum 8 
doses of  oral 200 mcg misoprostol were administered ev-
ery 4 hours to women with a history of  previous cesar-
ean section. The women were followed up for 48 hours, 
after which their condition was evaluated. Misoprostol 
treatment was accepted as unsuccessful in patients whose 
pregnancies were not terminated after 48 hours. In un-
successful cases, additional procedures such as induction 
with oxytocin (20 drops per minute with 5 IU oxytosin 
into 500 cc of  5% dextrose) and placement of  a Foley 
catheter into the uterine cavity were performed (Figure 
1).
The NCSS 2007 and PASS 2008 statistical software (Utah, 
USA) program was used for statistical analyses for the 
evaluation of  the findings of  the study. Pearson’s correla-
tion analysis was used for the detection of  relationships 
between the parameters, and the effects of  gestational 
week, biparietal diameter, and head circumference on the 
termination time were evaluated using linear regression 
analysis. P values <0.05 were considered significant. 
Figure 1. Consort Flow Diagram
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The distribution of  the fetal anomalies of  the 144 pa- tients who were diagnosed as having major fetal anoma-
lies incompatible with life is given in Table 2.
Among the 144 patients, the number of  women with a 
history of  cesarean sections was 44. The minimum and 
maximum values of  abortion/birth intervals in patients 
with a history of  cesarean section were 5 hours and 106 
hours, respectively; with a mean of  32±30 hours and a 
median of  18 hours. The minimum and maximum val-
ues of  abortion/birth intervals in multiparous women 
with no history of  cesarean section were 2 hours and 94 
hours respectively; with a mean of  23.6±22.5 hours and 
a median of  14.5 hours. The minimum and maximum 
values of  abortion/birth intervals in nulliparous patients 
without previous cesarean section were 7 hours and 126 
hours, respectively; with a mean of  32.9±24.2 hours and 
a median of  27 hours. The time from the initiation of  
medicine until abortion in nulliparous patients was sta-
tistically significantly longer compared with multiparous 
patients (p<0.05). The dispersion according to abortion/
birth intervals is presented in Table 3.
Table 1:  Distribution of Demographic Characteristics 
Demographic Characteristics Feticide  
Performed (n=99)     
Feticide  
Not Performed (n=45) 
Age (years) (Mean±SD) 26.56±5.0 28.32±7.1 
Gravida (Mean±SD) 2.33±1.61  2.63±1.09 
Parity (Mean±SD) 1.75±0.92   1.77±1.1   
Number of Abortions (Mean±SD) 1.50±0.99  1.52±0.82 
Nulliparous (n/percent) 30 (30.3%) 10 (22.2%) 
Multiparous (n/percent) 
Previous cesarean-section (n/percent) 
69 (69.7%) 
  32 (32.3%)     
           35 (77.7 
 
           12 (26.7%) 
 











CNS  25 (25.3) 11 (24.5) 36 (25) 
Multiple  24 (24.2) 9 (20.0) 33 (22.9) 
CVS  19 (19.2) 10 (22.2) 29 (20.1) 
Chromosomal  9 (9.1) 4 (8.9) 13 (9.1) 
Skeletal system  7 (7.1) 4 (8.9) 11 (7.6) 
Urinary system  5 (5.1) 2 (4.4) 7 (4.9) 
GIS  2 (2.0) - 2 (1.4) 
Other  8 (8.1) 5 (11.1) 13 (9) 
Total 99 (100) 45 (100) 144 (100) 
 
Results
The demographic features of  the 144 patients are given 
in Table 1. The mean age of  the patients was 27.47±6.0 
years. The mean gravida was 2.43±1.56, the mean par-
ity was 1.76±1.06, the mean number of  abortions was 
1.48±0.96, and the mean gestational week was 21.35±4.46. 
40 patients were nulliparous, and 104 were multiparous. 
44 out of  104 multiparous patients had experienced one 
or more cesarean deliveries. The mean termination times 
of  the patients was 34.60±27.31 hours.
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Feticide was achieved in 99 (68.8%) of  the 144 wom-
en before the administration of  misoprostol. In 71.5% 
(n=103), abortion/birth occurred in 48 hours.  
In 41 (28.5%) women, misoprostol failed. Misopros-
tol+oxytocin was administered to 24 (16.3%) of  the 41 
unsuccessful cases; misoprostol+Foley+oxytocin were 
administered to 12 (8.3%) of  the 41 unsuccessful cases, 
hysterotomy was performed for the 5 remaining patients 
whose labor action was unsuccessful.
Feticide was not performed to the remaining 45 cases. The 
termination durations of  the women with and without 
feticide were examined. The efficacy of  the misoprostol 
protocol was evaluated and compared between the two 
groups. There was no statistically significant difference 
in terms of  termination durations between the groups 
(p>0.05) (Table 4).
Although there were no statistically significant differenc-
es between the termination durations and femur length 
(FL) and abdominal circumference (AC) measurements 
(p>0.05), a statistically significant inverse relationship 
was detected with bi-parietal diameter (BPD) (termina-
tion duration is found to shorten with BPD increase) at 
a level of  34.3%. A statistically significant inverse rela-
tionship was detected between termination duration and 
head circumference (HC) (termination duration is found 
to shorten with HC increase) at a level of  36.3% (Table 5, 
Figure 1, Figure 2).
Table 3: Dispersion according to abortion/birth intervals (N=144) 








Multiparous (without history of 
cesarean section n=60) 2 94 23.6±22.5 14.5 
Nulliparous (n=40) 7 126 32.9±24.2 27 
Those with histories of caesarian 
sections (n=44) 5 106 32.0±30.0 18 
 
Table 4: The evaluation of the gestational weeks and termination durations, and termination 
condition of women who did and did not undergo feticide 
 
The evaluation of cases Feticide Performed 
(n=99) 




Successful n (%) 






Gestational Week (Mean±SD)  21.24±3.63  21.31±3.43 NS** 
Termination duration; hours (median)  35.37±27.55    32.42±27.04  NS*** 
*Fisher’s exact test **Student’s t-test  *** Mann-Whitney U test  NS: Not Significant 
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BPDTermination Duration 
                         *BPD: Biparietal diameter BPDTermination Duration                          *BPD: Biparietal diameter 
Figure 2. The relationship between termination duration and BDP 
Table 5: The relationships of BPD, HC, AC, and FL to termination durations 
 
 
r: Pearson’s correlation coefficient  




FL  0.150  0.192 
BPD  -0.343    0.020* 
HC  -0.363   0.015* 
AC                             -0.256           0.066 
African Health Sciences Vol 19 Issue 1, March, 2019 1549
30 of  the 44 patients with previous cesarean section 
resulted in abortion and the success rate was found as 
68.9%. In terms of  complications, 7 (4.8%) patients had 
nausea, 5 (3.45%) had vomiting, 6 (4.1%) had diarrhea, 20 
(13.8%) had fever, 9 (6.25%) had headache and dizziness, 
and failure of  method was determined in 41 (28.4%) pa-
tients. 90 (62.5%) of  the remaining 144 women had in-
complete abortions and required curettage. In our study, 
the high rate of  curettage after abortion was due to strict 
control measures for bleeding after abortion and routine 
cavity control for retained placenta.
 
                                                                         HC Termination Duration 
                                                                                *HC: Head circumference 
 
                                                                         HC Termination Duration 
                                                                                *HC: Head circumference
Figure 3. The relationship between termination duration and HC 
Discussion
In our retrospectively conducted study, we evaluated the 
diagnostic and treatment methods as well as the resulting 
complications of  women who were diagnosed as having 
fetal anomalies; therefore, determining the dispersion of  
these women according to anomaly type. Abortion/birth 
was achieved in 71.5% (103 cases) of  women during the 
first 48 hours. There was no significant difference be-
tween the termination durations of  the misoprostol pro-
tocol among women in whom feticide was and was not 
performed. There was no significant difference between 
the termination durations and fetal biometric measure-
ments, except for head diameters.
Gedikbaşı et al.9 evaluated 677 patients and divided these 
patients into two groups: early termination (<23 weeks) 
and late termination (>23 weeks). The most common 
indications in their study were central nervous system 
anomalies (57.7%), chromosome anomalies (11.7%), uro-
genital anomalies (8.4%), cardiovascular system anoma-
lies (4%), hydrops (3.8%), and maternal infections and 
diseases (3.2%). In multiple pregnancies, high incidenc-
es of  fetal structural and chromosomal anomalies were 
detected, along with poor maternal and fetal outcomes. 
Guillem et al.10 scanned a total of  996 patients between 
1989 and 2000 and detected fetal structural anomalies in 
39% and chromosome anomalies in 35%. Different from 
these studies, central nervous system anomalies were de-
tected as 25%, cardiovascular system anomalies as 20.2%, 
and chromosomal anomalies as 9.18% in our study. The 
number of  patients who met the inclusion criteria of  our 
study was smaller.
In our study, abortion/birth occurred in 48 hours with 
oral-vaginal misoprostol in 71.5% (n=103) of  the wom-
en. The method was deemed unsuccessful if  abortion/
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birth did not occur in 48 hours and abortion was achieved 
with additional methods. In 41 (28.5%) women, miso-
prostol failed. Misoprostol+oxytocin was administered to 
24 (16.3%) of  the 41 unsuccessful cases; misoprostol+-
Foley+oxytocin was administered to 12 (8.3%) of  the 41 
unsuccessful cases, hysterotomy was performed for the 5 
remaining patients whose labor action was unsuccessful. 
Öztürka et al11 administered 100 mcg misoprostol (Cy-
totec 200 mcg/2) into the posterior fornix of  the vagina 
followed by 100 mcg misoprostol (Cytotec 200 mcg/2) 
every two hours to the 30 cases in the oral group in their 
study that compared sublingual, vaginal, and oral uses of  
misoprostol. The same doses were repeated to women 
who did not have their abortions in 24 hours and their 
conditions at the end of  48 hours were evaluated. The 
success rates in the first 24 and 48 hours were 83.3% 
(n=25) and 90% (n=27), respectively. The success rate in 
the first 48 hours in that study was higher compared with 
our study. Different than this study, patients with Bishop 
scores of  3 and below who had no active labor action 
were included in our study, and the number of  patients in 
their study was smaller compared with our study. 
History of  cesarean section operations has become com-
mon among patients for whom second trimester termi-
nation is planned due to increasing rates of  cesarean sec-
tion in today’s practice. In women who have had previous 
cesarean section, uterine ruptures caused by misoprostol 
cause concerns regarding the use of  this drug12. Despite 
the increasing number of  publications reporting that 
misoprostol can be safely used in patients with transverse 
incisions in the lower segment of  the uterus for termina-
tion of  pregnancies in the second trimester, the real inci-
dence of  uterine rupture risk remains unknown13. There 
are studies reporting that misoprostol use is not contra-
indicated in patients whose histories are positive for ce-
sarian section operations, but also warning that caution 
must be taken in their follow-ups due to the high risk of  
uterine rupture12-14. In addition, the safety of  misopros-
tol use for termination of  second trimester pregnancies 
in women with uterine scars is still controversial. Many 
women with uterine ruptures that occur during the sec-
ond trimester have a history of  previous uterine surger-
ies15. In a study on 720 patients between the gestational 
weeks of  14-28 who had terminations in the second tri-
mester, 78 had one, 19 had two, and 4 had three previous 
cesarean section operation histories; Dickinson reported 
no rupture cases and also that misoprostol was safe to use 
in patients with histories of  cesarian section operations16. 
In their retrospective analysis of  91 patients, Aslan et al.17 
proved that misoprostol induction doubled the risk of  
uterine ruptures in patients with histories of  cesarian sec-
tion operations and urged caution in terms of  maternal 
safety. In our study, 44 women had uterine scars due to 
previous cesarean sections. The minimum and maximum 
doses of  misoprostol administered in this group were 3 
and 9 doses respectively, with a mean of  5±3 doses. The 
minimum and maximum times until the abortion were 5 
hours and 106 hours, respectively, with a mean of  32±30 
hours. The success rate in the first 48 hours was 68% 
(n=30). Although the number of  women with histories 
of  cesarean section operations was low, we detected no 
complications secondary to the use of  misoprostol. 
Placenta retention or incomplete abortions are import-
ant problems that may arise after terminations in the sec-
ond trimesters and require surgical intervention. In the 
first studies regarding misoprostol use for this purpose, 
more than 80% of  patients were reported to require cu-
rettage18,19. In our study, 90 (62.5%) of  the remaining 144 
women had incomplete abortions and required curettage. 
In Ozturka et al.s’ study regarding the comparison of  
sublingual, vaginal, and oral misoprostol use for second 
trimester terminations, the incomplete abortion rate was 
found to be high and similar in all three groups (sublin-
gual 70%, vaginal 69%, and oral 85.2%)11. Bugallo et al.20 
reported 89% complete abortion rates in patients until 
their 22nd gestational weeks. 
There was no difference between the women who did 
and did not undergo feticide in terms of  durations of  ter-
mination or complications in our study. Srisomboon et al. 
compared the abortion success rates of  89 women with 
dead and alive fetuses following intravaginal misopros-
tol administrations at the 12th, 24th, and 48th hours, and 
reported the abortion rates as 50%, 83% and 97% and 
15%, 54% and 92.5% respectively. The abortion success 
rate of  intravaginal misoprostol at the 12th and 24th hours 
was significantly lower in alive fetuses as compared with 
dead fetuses, but the success rates at the 48th hour were 
the same. There was no significant difference between the 
two groups in terms of  complications at the 12th, 24th, and 
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48th hours21.  In one study, the effect of  feticide on the 
duration of  labor induction was examined retrospectively 
and there was no significant difference noticed in the out-
come except that the group with feticide tended to have 
more procedures in the form of  manual extraction of  
placenta or uterine curettage or both (82.9 vs. 65.6%, P = 
0.01)22. The results also showed that performing feticide 
procedures had no effect on the termination duration. 
Another important point of  our study is the compari-
son of  BPD, AC, HC, and FL measurements as factors 
affecting termination duration and the conclusion that 
termination duration shortens as BPD and HC increases. 
However, AC and FL were not observed to have a direct 
effect on termination duration. 
Conclusion
The use of  misoprostol had no effect on termination du-
ration in patients who did and did not undergo feticide 
procedures in second trimester pregnancy terminations. 
The administration of  misoprostol treatment protocol is 
effective, safe, and successful in pregnant women with fe-
tal anomalies incompatible with life. Misoprostol decreas-
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